Table 1 Patient characteristics
Variable | Therapy received | |
|---|---|---|
Immuno, N = 461 | Target, N = 361 | |
Age at therapy start | ||
N | 46 | 36 |
Median (IQR) | 67 (60, 73) | 52 (48, 67) |
Range | 37, 92 | 26, 80 |
Survival time (months) | ||
N | 41 | 36 |
Median (IQR) | 17 (6, 26) | 20 (12, 29) |
Range | 0, 51 | 3, 51 |
Sex | ||
Female | 17 (37%) | 12 (33%) |
Male | 29 (63%) | 24 (67%) |
Response | ||
CR | 9 (21%) | 10 (28%) |
PD | 7 (17%) | 2 (5.6%) |
PR | 15 (36%) | 18 (50%) |
SD | 11 (26%) | 6 (17%) |
Status | ||
Alive | 32 (71%) | 23 (64%) |
Death | 13 (29%) | 13 (36%) |
Cause of death | ||
Alive or death by other causes | 36 (78%) | 23 (64%) |
Death by melanome | 10 (22%) | 13 (36%) |
Stage at therapy start | ||
IIIC | 2 (4.3%) | 6 (17%) |
IV | 1 (2.2%) | 1 (2.8%) |
IV_M1a | 12 (26%) | 6 (17%) |
IV_M1b | 12 (26%) | 4 (11%) |
IV_M1c | 19 (41%) | 18 (50%) |
IV_M1d | 0 (0%) | 1 (2.8%) |